XinRelease | XinBio and Neukio Biotherapeutics signed a strategic cooperation agreement
Date：2023-05-19 Views：
On May 17th, Suzhou XinBio Co., Ltd. signed a strategic cooperation agreement with Neukio Biotherapeutic (Shanghai) Co., Ltd. Mr. Shen Jianxing, Deputy Director of Wujiang Economic Development Zone, Mr. Gu Wei, Deputy Director of Wujiang Science and Technology Bureau, Mr. Meng Ruifeng, CEO of XinBio, Dr. Chi Shen of XinBio, CTO, Mr. Zhao Guochuang, CSO of XinBio, Mr. Wang Liqun, Chairman of Neukio, Dr. Zong Hongliang, Vice President of CMC of Neukio, Dr. Sun Mu, Vice President of Business Development and Strategy of Neukio, and Dr. Yan Qianhai, Senior Director of Process Development and Production of Neukio, attended the event and witnessed the signing.
As a supplier of CGT fully automated integrated solutions, XinBio has always been committed to the integration of research, production, and sales of equipment, consumables, and reagents, using technology to safeguard life and health. The signing of this cooperation agreement signifies that both parties will deepen their cooperation in research and development, technology, production, and other aspects. It will also further promote the high-quality development of XinBio and achieve mutual growth and progress with the industry.
Mr. Meng Ruifeng, CEO of XinBio, stated that XinBio is committed to becoming a comprehensive supplier of the entire CGT tool industry chain in China. Based on our core magnetic sorting platform, we have launched the first fully automatic cell manufacturing integrated machine SophCyte® Kunlun in China 。 In the future, distributed semi-automatic equipment, manual sorting kits, and matching sorting reagents which based on magnetic sorting will be gradually launched. Based on our antibody development platform and coupling process platform, we will gradually launch our sorting magnetic bead antibodies, flow cytometry detection antibodies, and corresponding quality control detection kits in the future. XinBio is very much looking forward to deepening cooperation with Neukio, striving to promote the entry of more accessible and commercially produced cell drugs into the market as soon as possible, and making fair contributions to the overall development of the cell drug industry and patient treatment.
Mr. Wang Liqun, Chairman of Neukio, believes that this strategic cooperation is based on the consensus and willingness of both parties to cooperate on the development needs of the new generation of universal cell therapy products. Both parties will fully leverage their respective expertise to provide solutions for large scale and automation of production process. As an innovative enterprise focusing on the development of iPSC derived CAR-NK technology, Neukio hopes to collaborate with XinBio to launch a fully automated universal cell manufacturing equipment, which will help the cell industry improve production efficiency and product stability, reduce costs, and achieve the successful development of a new generation of universal mass-produced and solid tumor-treatable immune cell products as soon as possible to benefit patients.
.jpg "640 (2).jpg")
Recommended news
400-863-1188
Add:1st and 3rd floors of Qinghe Maker, No. 1368 Longqiao Road, Wujiang District, Suzhou City
E-mainl:info@szxxbio.com
Copyright © 2024 Suzhou XinBio Co., Ltd.
and/or its affiliates. All rights reserved.
